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ABSTRACT
Diabetic kidney disease (DKD) is a major complication of diabetes, and serves as 
an important cause of end-stage renal disease (ESRD). The role of chronic inflammation 
in DKD is becoming widely accepted. Pancreatic stone protein/regenerating protein 
(PSP/reg) is a secretory protein, which is elevated in blood during infected conditions 
and organ failure. The aim of this study was to investigate the relationship between 
serum PSP/reg and DKD in patients with type 2 diabetes (T2DM). A total of 120 
subjects which includes newly diagnosed T2DM patients, diabetes patients without 
DKD, DKD patients, as well as healthy controls were enrolled in this study. Serum 
PSP/reg levels were significantly higher in DKD subjects compared with those of 
healthy controls (p < 0.001), newly diagnosed T2DM (p < 0.001) and diabetes 
patients without DKD (p < 0.001). PSP/reg levels correlated positively with glycated 
hemoglobin (HbA1c) (p < 0.001) and serum creatinine (p < 0.001). Meanwhile, serum 
PSP level was negatively correlated with estimated glomerular filtration rate (eGFR) 
(p < 0.001). The area under the curve (AUC) for presence of DKD was 0.854. In 
conclusion: PSP/reg levels are significantly up-regulated in DKD patients and might 
be related to renal injury. A follow-up study with a large cohort is needed.
INTRODUCTION
Diabetes mellitus is one of the most common 
metabolic disorders in the world. The prevalence of 
diabetes mellitus was estimated at 382 million in 2013, 
and is expected to reach 592 million by 2035, due to a 
dramatic increase in incidence [1]. As an important 
cause of disability, diabetes mellitus leads to various 
macrovascular and microvascular chronic complications. 
Among these complications, Diabetic kidney disease 
(DKD) is one of the major microvascular complications 
and is independently correlated with an increased risk 
of developing end stage renal failure (ESRD). ESRD 
is a heterogeneous disease with damage of nearly 
every aspect of the renal structure and function [2-
4]. A number of factors have been proposed to cause 
pathological changes in the kidney of diabetic patients, 
such as the interactions between hyperglycemia-induced 
hemodynamics and metabolic changes [5-7], as well as 
the accumulation of extracellular matrix (ECM) proteins 
in the glomerular and tubular compartments. However, the 
exact pathogenesis leading to DKD is not fully elucidated. 
Recently, accumulated evidence have demonstrated a 
significant role of chronic low-grade inflammation, termed 
as ‘microinflammation’ in both the development and 
progression of DKD [8-11].
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Pancreatic stone protein/regenerating protein (PSP/
reg) was originally identified in pancreatic calcified 
concrements, as a 14 kDa insoluble polypeptide belonging 
to the family of lectin binding proteins [12]. Its 16 kDa 
precursor has been observed mainly in the pancreas and 
is transiently elevated in acute and chronic pancreatitis 
[13]. Under healthy conditions PSP/reg is expressed 
at low levels in the pancreas, with normal serum levels 
between 10-15 ng/ml. Upon focal or systemic extra-
pancreatic inflammation, PSP/reg is strongly increased 
[14]. PSP/reg is elevated in various conditions, e.g. sepsis 
[15], ventilator associated pneumonia (VAP) [16], chronic 
obstructive pulmonary disease (COPD) exacerbation 
[17], and type 1 diabetes mellitus (T1DM) [18]. These 
observations indicated that PSP/reg might respond to 
infectious conditions and organ failure. Our previous 
study also found that levels of PSP/reg were up-regulated 
in type 2 diabetes mellitus (T2DM) and diabetic chronic 
complications [19]. 
Understanding the concept that diabetic 
microangiopathy is associated with inflammation and an 
important factor in the development of DKD, we evaluated 
whether serum PSP/reg levels might be associated with 
DKD and partly predict the future risk. Therefore, we 
conducted this study to investigate the association between 
PSP/reg and DKD in T2DM patients.
RESULTS
Participants and clinical analysis at baseline
A total of 120 subjects (65 males, 55 females; age 
range 30-75 years) were enrolled in the study, and were 
divided into four study populations: healthy control, newly 
diagnosed T2DM patients, T2DM patients without DKD, 
and DKD patients. The main clinical and biochemical 
characteristics of these four study populations are 
summarized in Table 1.
Significantly elevated PSP/reg levels were detected 
in DKD patients
We measured fasting serum PSP/reg levels in all 
participants using an enzyme-linked immune sorbent 
assay (ELISA) [15]. Serum levels of PSP/reg from control 
subjects and diabetic patients are shown in Figure 1. PSP/
reg was elevated in T2DM patients and were significantly 
different as compared to the healthy controls. Notably, we 
found that PSP/reg levels were remarkably higher in the 
DKD group (50.32 ng/ml ± 20.21) compared with those 
in healthy controls (14.16 ng/ml ± 4.04, p < 0.001), newly 
Figure 1: Serum levels of PSP/reg in different groups of the study population. PSP/reg serum levels increased significantly in 
DKD patients (50.32 ng/ml ± 20.21) as compared to healthy controls, newly diagnosed (18.74 ng/ml ± 3.84, p < 0.001) and T2DM without 
DKD patients (25.84 ng/ml ± 10.49, p < 0.001). Onset, newly diagnosed T2DM; data are presented as mean ± SD, *p < 0.05, **p < 0.001.
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diagnosed (18.74 ng/ml ± 3.84, p < 0.001) and T2DM 
without DKD patients (25.84 ng/ml ± 10.49, p < 0.001).
Serum PSP/reg levels correlated with HbA1c, 
eGFR, serum creatinine, urinary albumin, and 
blood pressure
A significant correlation between PSP/reg level 
and glycated hemoglobin (HbA1c, Spearman’s rank 
correlation coefficient 0.547, p < 0.001, Figure 2A) in all 
the participants was noted. Simple correlations between 
PSP/reg and the systolic blood pressure (Spearman’s rank 
correlation coefficient 0.479, p < 0.001, Supplementary 
Figure S1A) and diastolic blood pressure (Spearman’s rank 
correlation coefficient 0.469, p < 0.001, Supplementary 
Figure S1B) were also found. Meanwhile, Serum PSP/
reg levels prominently correlated with serum creatinine 
(Spearman’s rank correlation coefficient 0.492, p < 0.001, 
Figure 2B), urinary albumin (UA, Spearman’s rank 
correlation coefficient 0.620, p < 0.001, Figure 2C) and 
negatively correlated with estimated glomerular filtration 
rate (eGFR, Spearman’s rank correlation coefficient 
-0.502, p < 0.001, Figure 2D) and creatinine clearance 
rate (CCr, Spearman’s rank correlation coefficient -0.301, 
p = 0.001). After adjusting for age, sex, BMI, diabetes 
duration and blood pressure, significant correlations 
among PSP/reg and HbA1c (p = 0.014), eGFR (p < 0.001), 
creatinine (p < 0.001), UA (p < 0.001), CCr (p < 0.001) 
were still found.
Relationship between PSP/reg and DKD
We set out to assess the predictive value of PSP/
reg in T2DM by receiver operating characteristic (ROC) 
analysis. The area under the curve (AUC) of PSP/reg for 
presence of DKD was 0.854 (Figure 3). Furthermore, 
ROC analysis revealed that the optimal cut-off point of 
PSP/reg was 30.4 ng/ml to indicate DKD (Youden index 
= 0.65, sensitivity, 73.3%; specificity, 91.7%).
DISCUSSION
DKD is one of the most prevalent chronic 
complications in patients with diabetes. Glomerular injury 
is regarded as an early sign of DKD, and microalbuminuria 
is a potent indication of DKD progression [20]. Here 
we show that PSP/reg is significantly increased during 
progression of DKD, correlating with major parameters 
of T2DM. 
Increasing observations suggest that many 
diabetic patients with normoalbuminuria might develop 
nephropathy [21]. On the other hand, not all patients 
Table 1: Clinical characteristics of subjects
Group Healthy control Onset T2DM without DKD DKD
Age (years) 56.50 [53.75-58.50] 60.00 [56.75-65.00] 63.50 [56.50-67.40] 57.50[54.35-61.20]
Gender male (%) 17(56.67) 14 (46.7)  18 (60.0) 16 (53.33)
Duration (months) —  4.93 ±3.18  101.90± 52.87 114.97 ± 53.60
Smoking (%) 5 (16.67)  10 (33.33) 7 (23.33)  4 (13.33)
BMI (kg/cm2) 22.21±2.07  25.51 ± 3.44 24.36 ± 3.35  25.30 ± 3.58
Systolic BP (mmHg) 112.57 ± 8.65  118.20± 9.07 131.27 ± 16.26*  136.97 ± 14.60*
Diastolic BP (mmHg)  72.00 ± 7.85  73.80 ± 7.12  76.57 ± 9.22  82.83 ± 7.72
TC (mmol/L) 4.13 ± 0.75  4.53 ± 0.80 4.80 ± 1.45 4.99 ± 1.40*
TG(mmol/L) 1.15 ± 0.26  1.58 ± 0.43*  1.28 ± 0.26  1.98 ± 1.36*
HDL-cholesterol (mmol/l) 1.31 ± 0.32 1.12± 0.29  1.15 ± 0.25  1.11 ± 0.21*
LDL-cholesterol (mmol/l) 2.23 ±0.43  2.73 ± 0.54  2.89 ± 0.90  2.96 ± 0.99
OGTT FPG (mmol/l)  5.15 [4.90–5.30]  7.27 [6.74–8.23]*  5.55 [4.77–7.24]*  7.33 [5.86–8.14]*
OGTT 2hPG (mmol/l) 6.05 [5.88–6.30] 11.13 [8.89–15.27]*  10.10 [7.08–12.18]*  11.05 [8.73–14.23]*
HbA1c (%)  5.20 [5.08–5.33] 7.55 [6.30–8.53]*  7.05 [6.18–8.23]*  8.25 [7.58–9.10]*
Creatinine (μmol/L) 65.27 ± 8.15 62.12 ± 4.59  67.93 ± 10.47  104.77 ± 25.90*
BUN (mmol/L)  5.50 ± 0.73 4.55 ± 0.62  4.90 ±1.30 6.18 ± 1.46*
UA (mg/24h)  11.90 [4.75-17.26] 15.30 [11.52-22.75]  23.10 [14.98-26.30] 65.10 [31.44-150.0]*
eGFR (ml/min/1.73 m2) 105.20 ± 11.34 106.21 ± 12.99  100.73 ± 10.86  63.53 ± 19.10*
CCr (ml/min) 97.02 ± 17.58 103.64 ± 16.77  98.57 ± 20.39  60.72 ± 22.79*
Human PSP (ng/ml) 14.16 ± 4.04 18.74 ± 3.84*  25.84 ± 10.49*  50.32± 20.21*
Clinical characteristics of different groups of subjects. Data are expressed as mean ± SD or as percentages for normal 
distribution. Non-normally distributed values are presented as median (IQR). BMI, body mass index; Systolic BP, systolic 
blood pressure; Diastolic BP, diastolic blood pressure; TC, total cholesterol; TG, Triglyceride; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; FPG, Fasting plasma glucose; 2hPG, 2h plasma glucose; HbA1c, hemoglobin A1c;BUN, blood 
urea nitrogen; UA, urinary albumin; eGFR, estimated glomerular filtrations rate; CCr, Creatinine Clearance Rate.*p < 0.05 
compared with healthy control.
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Figure 2: Correlation analysis of PSP/reg in T2DM patients. A. Correlation of PSP/reg with HbA1c (Spearman r = 0.547, p < 
0.001). B. Correlation of PSP/reg with serum creatinine (spearman r = 0.492, p < 0.001). C. Correlation of PSP/reg with UA (Spearman r 
= 0.620, p < 0.001). D. Correlation of PSP/reg with eGFR (Spearman r = -0.502, p < 0.001). Lines represent the trend calculated by linear 
regression.
Figure 3: ROC curve analysis. PSP/reg predicts the incidence of DKD. The 30.4 ng/mL cut-off reveals a sensitivity of 73.3 % and a 
specificity of 91.7 % to predict the incidence of DKD.
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with proteinuria are likely to develop progressive renal 
dysfunction [22, 23]. This demonstrates that different 
mechanisms might contribute to the pathogenesis of DKD. 
In recent years, a substantial body of evidence suggests 
that immune and inflammatory processes play a critical 
role in the development and progression of DKD. Several 
studies suggested that cytokines, such as tumor necrosis 
factor-α (TNF- α) and interleukin-6 (IL-6) [11, 24, 25], 
and chemokines, e.g. monocyte chemoattractant protein-1 
(MCP-1), and C-X-C chemokine ligand 16 (CXCL16) 
[26], were involved in the inflammatory process of DKD. 
In our previous study, elevated PSP/reg levels 
were found in patients with T2DM and diabetic chronic 
complications as compared to healthy controls [19]. In the 
present study, we analyzed PSP/reg levels in patients with 
DKD and revealed a close relationship between PSP/reg 
levels and DKD in T2DM patients. Serum PSP/reg was 
significantly increased in the DKD group as compared 
to T2DM without DKD patients and more importantly, 
high serum PSP/reg level seemed associated with renal 
injury and insufficiency. These results further imply 
that inflammation may be important in facilitating the 
development and progression of DKD [4].
In the current investigation, we found correlations 
between PSP/reg levels and HbA1c, as well as fasting 
blood glucose(FBG) and 2-h postprandial glucose(2hPG), 
implying that the elevation of PSP/reg levels might have a 
close association with beta cell dysfunction. This finding is 
in accordance with recent data suggesting that upregulated 
extracellular glucose concentrations reinforce gene 
expression of PSP/reg, which may indicate an important 
feedback loop for the regulation of beta-cell mass [27]. 
Meanwhile, consistent positive correlations of PSP/reg 
levels with serum creatinine, UA and negative correlation 
with eGFR suggest that serum PSP/reg levels closely 
reflect glomerular injury and declining renal function in 
T2DM patients. 
For future risk assessment, we calculated the AUC 
of PSP/reg for presence of DKD, which was 0.854 (95 
%CI: 0.764-0.944). In the process of this analysis, we 
identified a cut-off value for PSP/reg at 30.4 ng/ml in 
T2DM patients. This was the most significant parameter 
associated with the occurrence of DKD. In our previous 
study, a PSP/reg cut-off of 22 ng/ml in nondiabetic group 
was found to indicate the incidence of T2DM. Here, we 
investigated this higher cut-off to have a better predictive 
value for DKD. 
In summary, our study provides clinical evidence 
that serum levels of PSP/reg are highly increased in 
subjects with DKD and are positively associated with 
HbA1c and negatively with eGFR. These data imply that 
PSP/reg may be associated with renal injury in T2DM 
patients. There are also some limitations in our study. 
First, as a preliminary study, the sample size of this 
study is relatively small, and as the nature of a cross-
sectional design, further prospective studies with larger 
study population and different stages of DKD patients 
are required to determine whether PSP/reg can be used as 
a potential biomarker for diagnosing and evaluating the 
onset and development of DKD. Second, to strengthen our 
results on the role of PSP/reg as a marker of renal injury 
and inflammation in the disease progression of DKD, 
correlations with serum cystatin C (Cys C), homocysteine 
(Hcy) and other inflammatory markers such as C reactive 
protein (CRP), tumor necrosis factor-alpha (TNF-α) are 
needed.
Despite these limitations, our preliminary data 
suggest that PSP/reg may help detect patients at high 
risk for kidney injury in T2DM. Therefore, it is worth 
considering the potential role of serum PSP/reg level 
as a supplementary indicator of DKD. An enhanced 
understanding of the inflammatory response in the diabetic 
kidney may be beneficial to facilitate the identification of 
novel therapeutic strategies for the treatment of DKD.
MATERIALS AND METHODS
Ethics
The study was approved by the institutional clinical 
research ethics committee of Zhongda Hospital, Southeast 
University and adhered to the principles of the Declaration 
of Helsinki. All subjects provided informed consent to 
participate in the study.
Study population
A total of 120 subjects including those of newly 
diagnosed T2DM patients (n = 30), diabetes patients 
without DKD (n = 30) and with DKD (n = 30), as well 
as healthy controls (n = 30) were enrolled from Zhongda 
Hospital, Southeast University, China. The diagnostic 
criteria for T2DM was based on American Diabetes 
Association (ADA) criteria 2014. DKD was defined 
according to either the presence of microalbuminuria (30 
to 299 mg albumin/24 h or an albumin to creatinine ratio 
[ACR] of 30 to 299 mg/g) or macroalbuminuria ( > 300 
mg albumin/24 h or ACR > 300 mg/g). DKD was also 
classified on the basis of renal biopsy.
Subjects with any of the following conditions 
were excluded from this study:(1) T1DM; (2) acute 
complications of diabetes including diabetic hyperosmolar 
coma, ketoacidosis, lactic acidosis, hypoglycemic coma; 
(3) history of other renal disease except DKD; (4) active 
or chronic infection or inflammatory disorders, neoplastic 
disorders, severe liver dysfunction; (5) pregnancy; (6) on 
medicine which affects blood or urine glucose levels.
We also included 30 healthy volunteers who 
underwent a regular health examination at Zhongda 
Hospital, Southeast University, China. All healthy subjects 
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were selected based on the results of laboratory tests and a 
physician’s questionnaire.
Data collection
A full clinical assessment was obtained by a 
standardized questionnaire. Anthropometric measurements 
including height, weight, waistline, hipline, and waist 
hip rate (WHR) were obtained. BMI was calculated 
as weight (kg) divided by the square of the height (m). 
Personal information such as age, gender, smoking 
behavior, hypertension, duration of diabetes, family 
history of diabetes, medical history was also recorded. 
All participants underwent an oral glucose tolerance test 
(OGTT) after a 12-h overnight fast with measurement of 
FBG, 2hPG, and HbA1c. Blood samples were collected 
in BD vacutainers, and then centrifuged at 1500xg for 20 
minutes. Serum was aliquoted and frozen at -80°C until 
the assay was performed. Other clinical biochemical 
parameters, such as total cholesterol (TC), triglyceride 
(TG), high-density lipoprotein (HDL), low-density 
lipoprotein (LDL); HbA1c, creatinine (Cr), blood urea 
nitrogen (BUN), eGFR, CCr, UA were measured based on 
standard methods.
PSP/reg enzyme-linked immunosorbent assay
The ELISA to quantify human PSP/reg was 
performed as previously described [15], using Guinea pig 
anti-human recombinant PSP/reg antibodies. Deep frozen 
serum samples were used for PSP/reg measurements, 
and the IgG were purified by affinity chromatography on 
protein A columns. A sandwich ELISA was performed on 
96-well plates. The plates were blocked with 1% bovine 
serum albumin (BSA) in Tris-buffered saline (TBS) for 
1 h. Guinea pig anti-PSP/reg antibody was then coated 
to the bottom. Subsequently, samples were pre-diluted in 
TBS/BSA and loaded in duplicate wells, incubating for 2 
h. After washing, a second antibody, rabbit anti-PSP/reg, 
was then incubated and detected by phosphatase-coupled 
anti-rabbit IgG [28]. The reaction of the phosphatase 
with a substrate was determined on a multiplate reader 
(Dynatech), and subjects’ serum PSP/reg levels were 
compared with standard amounts of recombinant human 
PSP/reg protein.
Statistical analysis
Statistical analyses were performed by the SPSS 
19.0 software. Data are shown as mean ± standard 
deviation (SD) or as percentages for normal distribution. 
Non-normally distributed values are presented as median 
(interquartile range [IQR]). Correlations of PSP/reg and 
clinical parameters were performed using Pearson’s 
correlations or Spearman’s rank correlation coefficient 
when appropriate. Differences of PSP/reg between groups 
were determined by analysis of variance (ANOVA). AUC 
values were presented with 95 % confidence intervals 
(95%CI). Cut-off was identified by Youden’s index. 
Correlations and differences were defined as significant 
at p < 0.05.
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